At least 21 biotechs and pharmas are slated to report earnings this week. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Celgene Corp. (NASDAQ:CELG) and Meridian Bioscience Inc. (NASDAQ:VIVO) all are expected to post quarterly EPS growth of 20% or more. Alexion, which markets hemolytic anemia drug Soliris eculizumab, is anticipated to post a 42% increase in revenues to $262.7 million, while revenues for big biotech Celgene are expected to be up 15% to $1.4 billion. 2Q12 revenues for diagnostic company